Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
Open Access
- 24 May 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (2) , 200819
Abstract
No abstract availableKeywords
Funding Information
- Leukemia & Lymphoma Society
This publication has 43 references indexed in Scilit:
- CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell ResponseCell Metabolism, 2018
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with NeuroblastomaMolecular Therapy, 2017
- Chromatin states define tumour-specific T cell dysfunction and reprogrammingNature, 2017
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibitionJournal of Clinical Investigation, 2016
- Leucine Metabolism in T Cell Activation: mTOR Signaling and BeyondAdvances in Nutrition, 2016
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsNature Medicine, 2015
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cellsBlood, 2014
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNature Reviews Immunology, 2011
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Regulation of intracellular levels of NAD: A novel role for CD38Biochemical and Biophysical Research Communications, 2006